Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Two Adalimumab Formulations in RA
NCT01561313Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2012
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Mean Injection Site Pain on a Visual Analogue Scale (VAS). Started Mar 2012; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01561313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561313.